Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular Risk VASCEPA becomes the first and only FDA-approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in high-risk patients approved for treatment - Millions of people in the United States qualify as treatment candidates For VASCEPA - Cardiovascular disease events, including heart attack, stroke and cardiovascular death, occur in the United States every 14 seconds and are...